Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Thalamic Volume and Axonal Density Correlates with Cognitive Function in Multiple Sclerosis Patients Treated With Fingolimod
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-008

To determine correlations between cognitive function in fingolimod treated multiple sclerosis (MS) patients and 7 tesla (7T) magnetic resonance imaging (MRI) measures.

Cognitive dysfunction is common in MS and can impair processing speed, episodic memory, and executive function. MRI studies have demonstrated associations between several MRI metrics and cognitive functioning in MS, including thalamic volume and brain parenchymal fraction. Fingolimod is an MS therapy that has a protective effect on brain volume. We elected to study the relationship between 7T MRI metrics and cognitive functioning in MS patients taking fingolimod.

We recruited MS patients to undergo 7T brain MRI and cognitive testing including the symbol digit modalities test (SDMT), selective reminding test (SRT), and the trail making, color, and verbal subtests of the Delis-Kaplan Executive Function System (DKEFS). Cortical thickness, brain parenchymal fraction, thalamic volume (TV), and thalamic axon and myelin densities were derived. Spearman correlations were calculated between neuropsychological tests and MRI metrics, and a bootstrap bias-corrected and accelerated method was used to calculate 95% confidence intervals (CI).

We enrolled 15 MS patients with mean age 42.4 years (SD=5.6), mean disease duration 8.5 years (SD=4.1) and median expanded disability status scale 3 (IQR=1.5-3.5). TV was significantly correlated with DKEFS trail making performance (ρ=0.54, 95%CI=0.03-0.84) and long term storage on the SRT (ρ=0.61, 95%CI=0.02-0.87). Thalamic axon density was significantly correlated with DKEFS verbal performance (ρ=0.44, 95%CI=0.01-0.73) but thalamic myelin density was not significantly correlated with cognitive performance. Moderate correlations that did not reach significance included TV with consistent long term retrieval on the SRT (ρ=0.55, 95%CI=-0.03-0.83) and cortical thickness with recall at 30 minutes on the SRT (ρ=0.47, 95%CI=-0.04-0.77). The SDMT did not strongly correlate with any MRI metrics.

Thalamic volume and axonal density significantly correlated with measures of cognitive flexibility, verbal learning, and retrieval.

Authors/Disclosures
Devon Conway, MD
PRESENTER
Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.
Sarah M. Planchon Pope, PhD, CCRP (Cleveland Clinic) Dr. Planchon Pope has nothing to disclose.
No disclosure on file
Kunio Nakamura, PhD (Cleveland Clinic) Dr. Nakamura has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for INmune Bio. The institution of Dr. Nakamura has received research support from Biogen. The institution of Dr. Nakamura has received research support from PCORI. The institution of Dr. Nakamura has received research support from NIH. The institution of Dr. Nakamura has received research support from Genzyme. The institution of Dr. Nakamura has received research support from NIH. The institution of Dr. Nakamura has received research support from Genzyme. The institution of Dr. Nakamura has received research support from Novartis. The institution of Dr. Nakamura has received research support from DOD. Dr. Nakamura has received intellectual property interests from a discovery or technology relating to health care.
Nicholas Thompson The institution of Nicholas Thompson has received research support from EMD Serono.
No disclosure on file
Daniel Ontaneda, MD, PhD, FÂé¶¹´«Ã½Ó³»­ (Cleveland Clinic) Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.